Drug intelligence / Profile preview

klotho

Development stage
Preclinical
Lead developer
Klotho Neurosciences
Modality
Gene Therapies, Recombinant Proteins and Enzymes
Administration
Intravenous, Subcutaneous, Intramuscular, Intrathecal
01

Overview

Klotho is a naturally occurring human protein encoded by the KL gene and exists in three subfamilies: α-klotho (alpha), β-klotho (beta), and γ-klotho (gamma). The term "klotho" typically refers to α-klotho unless otherwise specified. Klotho functions as a type-I single-pass transmembrane protein with both membrane-bound and soluble forms. It acts as a co-receptor for fibroblast growth factors—α‑klotho for FGF23 and β‑klotho for FGF19/FGF21—regulating phosphate and vitamin D metabolism. Klotho modulates several molecular pathways including Wnt signaling, hypoxia-inducible factor pathway, insulin/insulin-like growth factor 1 signaling, and exerts antioxidative effects. Its deficiency is associated with accelerated aging phenotypes such as cognitive impairment, osteoporosis, arteriosclerosis, chronic kidney disease progression, cardiovascular diseases (including coronary artery disease and left ventricular hypertrophy), diabetes risk increase, muscle atrophy/frailty in aging populations as well as neurodegenerative disorders like Alzheimer’s disease. Overexpression or supplementation of klotho has been shown in animal models to extend lifespan and improve physical/cognitive health[1][3][4][5].

Other names
α-klothobeta-klothoγ-klothoalpha-klothogamma-klotho
02

Targets

FGFR1 (Fibroblast growth factor receptor 1)FGFR3 (Fibroblast growth factor receptor 3)IGF-1R (Insulin-like growth factor 1 receptor)TGFBR2 (TGF-β receptor type 2)

Beyond the preview

Go deeper on klotho.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on klotho.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call